Lixisenatide meets diabetes GOAL

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said once-daily lixisenatide as an add-on to basal insulin with or without sulfonylurea met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo in the Phase III GETGOAL-L-ASIA trial to treat Type II diabetes. The double-blind, Asian trial enrolled 311 patients inadequately control with basal insulin. ...